Option chain shows key data for Portage Biotech's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Portage Biotech.

Portage Biotech (NASDAQ:PRTG) Stock, Option Chain

Portage Biotech

Portage Biotech Inc is engaged in researching and developing pharmaceutical and biotech products through clinical proof of concept with an initial focus on unmet clinical needs. It is an immune-oncology company focused on overcoming immune resistance and currently managing 10 immuno-oncology assets at various development stages. Its pipeline products include IMM-60; IMM60 + Cell Therapy; (IMM60 / NY-ESO-1) + Keytruda and others.

Intel, Cleanspark, Super Micro Computer, Upstart, Tesla: Why These 5 Stocks Are On Investors' Radars Today

Earnings

News

Markets

Trading Ideas

APDN

AUID

CERO

COMM

CRVS

EFSH

FSBW

NIVF

NUKK

PRTG

PRZO

PTPI

RZLV

SHLT

SSBK

TNXP

VSTE

Why Corvus Pharmaceuticals Shares Are Trading Higher By Around 22%; Here Are 20 Stocks Moving Premarket

pharmaceutical ARDX Ardelyx

Movers

Portage Biotech stock is trading higher after the company announced it signed a letter of intent with Immunova for the potential sale of its subsidiary.

What&#39;s Going On With Portage Biotech Shares Tuesday?

Energy stocks

Equities

Eurozone

Commodities

DBGI

QUBT

TNYA

VCNX

Crude Oil Down Over 1%; US Industrial Production Declines In November

Portage Biotech Inc

Press Releases

Portage Biotech Announces 1-for-20 Reverse Stock Split

Portage Biotech Reports Fiscal Year-Ended March 31, 2024 Financial Results and Business Update

Portage Biotech Reports Results for Fiscal Quarter Ended June 30, 2024 and Business Update

"Stocks Under $1 Gaining Momentum: WBUY, KAVL, OMEX, PRTG, RJDG – Driving Innovation, Market Trends, and Growth Potential"

Portage Biotech Reports Results for Fiscal Quarter Ended September 30, 2024

Portage Biotech Announces Receipt of Nasdaq Noncompliance Letter

Portage Biotech Announces Letter of Intent with Immunova for an Option to Acquire iOx Therapeutics, Ltd

Management

General

Portage Biotech Announce Re-Launch of Adenosine Subsidiary as Independently Managed Company; Appointment of Peter Molloy to Lead New Company

Financing

Portage Biotech Announces Completion of $2.15 Million Private Financing

Portage Biotech Receives Extension of Time to Attain Compliance With Stock Exchange Continued Listing Requirements

KAVL

OMEX

RJDG

WBUY

AIM ImmunoTech

Ainos

Apollomics Inc. - Class A Ordinary Shares

Apollomics

Aptorum Group Limited - Class A Ordinary Shares

Aptorum Gr

Brainstorm Cell Therapeutics Inc. - Common Stock

Brainstorm Cell

bioAffinity Technologies, Inc. - Common Stock

bioAffinity Technologies

Can-Fite Biopharma Ltd Sponsored ADR (Israel)

Can Fite Biofarma

Creative Medical Technology Holdings, Inc. - Common Stock

Creative Medical Tech

Carmell

Cyclerion Therapeutics, Inc. - Common Stock

Cyclerion Therapeutics

Dermata Therapeutics, Inc. - Common Stock

Dermata Therapeutics

Dogwood Therapeutics, Inc. - Common Stock

Dogwood Therapeutics

Ensysce Biosciences

Galecto

GT Biopharma

Indaptus Therapeutics, Inc. - Common Stock

Indaptus Therapeutics

Klotho Neurosciences, Inc. - Common Stock

Klotho Neurosciences

Phio Pharmaceuticals Corp. - Common Stock

Phio Pharma

Sunshine Biopharma

SILO Pharma

Silexion Therapeutics Corp - Ordinary Shares

Silexion Therapeutics

Soligenix

Turnstone Biologics

Xenetic Biosciences

XTL Biopharmaceuticals Ltd. - American Depositary Shares

XTL Biopharmaceuticals

Cantor Fitzgerald

Oppenheimer

Comments

Portage Biotech

Portage Biotech (PRTG) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga